Feed LIANY
Summary
47 / 100 · Bulios Score
Valuation 100Growth 0Profitability -Quality 21Debt 100Stability 11
What speaks for it
- It has no debt and holds $9.39M in cash.
- The share price is below the Bulios Fair Price.
What to watch
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price
Current price $0.06
P/E today 1.3
Biotechnology industry median
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 1.3 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
2021202220232024202520262027
Diluted EPS (USD)
2021202220232024202520262027
- Analyst estimate
There is not enough revenue history yet to say how fast it grows.
Growth in detailDoes it make money?
Income figures for the last 12 months are not available.
Profitability in detailIs it financially healthy?
YesCash and short-term investments $9.39M
Debt $0.00
It has no debt.
Financial health in detailDoes it pay a dividend?
No20212022202320242025
It pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 1
- Hold 1
- Sell 1
No analyst has published a price target.
33% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.